ID

13364

Description

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00005072

Lien

https://clinicaltrials.gov/show/NCT00005072

Mots-clés

  1. 09/02/2016 09/02/2016 -
Téléchargé le

9 février 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00005072

Eligibility Prostate Cancer NCT00005072

Criteria
Description

Criteria

patient characteristics: age: 18 and over. performance status: karnofsky 80-100% or eastern cooperative oncology group (ecog) 0 or 1. life expectancy: not specified. hematopoietic: white blood cell count (wbc) greater than 3,000/mm3. platelet count greater than 100,000/mm3. hemoglobin greater than 9.0 g/dl. hepatic: bilirubin normal. serum glutamic oxaloacetic transaminase (sgot) or serum glutamic-pyruvic transaminase (sgpt) less than 3 times upper limit of normal. albumin greater than 3 g/dl. prothrombin time (pt) and partial thromboplastin time (ptt) normal. hepatitis b surface antigen negative. renal: creatinine normal. cardiovascular: no uncontrolled hypertension. no significant cardiovascular disease, e.g.: history of ventricular dysfunction; congestive heart failure; symptoms of coronary artery disease; history of any ventricular arrhythmia; prior myocardial infarction. other: hiv negative. fertile patients must use effective double-barrier contraception during and for 3 months after study participation. no active autoimmune disease. no active infection requiring iv antibiotics. no uncontrolled diabetes mellitus. no significant psychiatric disorder that would preclude study. no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer.
Description

patient characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0206065
UMLS CUI [3]
C1520224
UMLS CUI [4]
C0023508
UMLS CUI [5]
C0518015
UMLS CUI [6]
C1278039
UMLS CUI [7]
C0201899
UMLS CUI [8]
C0201836
UMLS CUI [9]
C0201838
UMLS CUI [10]
C0033707
UMLS CUI [11]
C0030605
UMLS CUI [12]
C0019163
UMLS CUI [13]
C0201976
UMLS CUI [14]
C0007222
UMLS CUI [15]
C0020538
UMLS CUI [16]
C0019682
UMLS CUI [17]
C0700589
UMLS CUI [18]
C0004364
UMLS CUI [19]
C0003232
UMLS CUI [20]
C0011849
UMLS CUI [21]
C0004936
UMLS CUI [22]
C0006826
prior concurrent therapy: biologic therapy: no prior leuvectin. chemotherapy: at least 3 weeks since prior chemotherapy (6 weeks for mitomycin or hydroxyurea). endocrine therapy: no prior hormonal therapy for prostate cancer. radiotherapy: see disease characteristics. at least 3 weeks since prior radiotherapy. surgery: at least 1 month since prior intrathoracic or intra-abdominal surgery. at least 2 weeks since other prior major surgery. other: at least 10 days since prior anticoagulants or non-steroidal anti-inflammatory agents. no neoadjuvant or other concurrent anticancer drug therapy. no concurrent immunosuppressive drugs. no other concurrent experimental therapy.
Description

patient characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
UMLS CUI [2]
C0677671
UMLS CUI [3]
C0392920
UMLS CUI [4]
C0279025
UMLS CUI [5]
C1522449
UMLS CUI [6]
C0543467
UMLS CUI [7]
C0003280
UMLS CUI [8]
C0003211
UMLS CUI [9]
C0600558
UMLS CUI [10]
C0021081
UMLS CUI [11]
C2348568

Similar models

Eligibility Prostate Cancer NCT00005072

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
patient characteristics
Item
patient characteristics: age: 18 and over. performance status: karnofsky 80-100% or eastern cooperative oncology group (ecog) 0 or 1. life expectancy: not specified. hematopoietic: white blood cell count (wbc) greater than 3,000/mm3. platelet count greater than 100,000/mm3. hemoglobin greater than 9.0 g/dl. hepatic: bilirubin normal. serum glutamic oxaloacetic transaminase (sgot) or serum glutamic-pyruvic transaminase (sgpt) less than 3 times upper limit of normal. albumin greater than 3 g/dl. prothrombin time (pt) and partial thromboplastin time (ptt) normal. hepatitis b surface antigen negative. renal: creatinine normal. cardiovascular: no uncontrolled hypertension. no significant cardiovascular disease, e.g.: history of ventricular dysfunction; congestive heart failure; symptoms of coronary artery disease; history of any ventricular arrhythmia; prior myocardial infarction. other: hiv negative. fertile patients must use effective double-barrier contraception during and for 3 months after study participation. no active autoimmune disease. no active infection requiring iv antibiotics. no uncontrolled diabetes mellitus. no significant psychiatric disorder that would preclude study. no other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer.
boolean
C0001779 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
C1520224 (UMLS CUI [3])
C0023508 (UMLS CUI [4])
C0518015 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
C0201836 (UMLS CUI [8])
C0201838 (UMLS CUI [9])
C0033707 (UMLS CUI [10])
C0030605 (UMLS CUI [11])
C0019163 (UMLS CUI [12])
C0201976 (UMLS CUI [13])
C0007222 (UMLS CUI [14])
C0020538 (UMLS CUI [15])
C0019682 (UMLS CUI [16])
C0700589 (UMLS CUI [17])
C0004364 (UMLS CUI [18])
C0003232 (UMLS CUI [19])
C0011849 (UMLS CUI [20])
C0004936 (UMLS CUI [21])
C0006826 (UMLS CUI [22])
patient characteristics
Item
prior concurrent therapy: biologic therapy: no prior leuvectin. chemotherapy: at least 3 weeks since prior chemotherapy (6 weeks for mitomycin or hydroxyurea). endocrine therapy: no prior hormonal therapy for prostate cancer. radiotherapy: see disease characteristics. at least 3 weeks since prior radiotherapy. surgery: at least 1 month since prior intrathoracic or intra-abdominal surgery. at least 2 weeks since other prior major surgery. other: at least 10 days since prior anticoagulants or non-steroidal anti-inflammatory agents. no neoadjuvant or other concurrent anticancer drug therapy. no concurrent immunosuppressive drugs. no other concurrent experimental therapy.
boolean
C0087111 (UMLS CUI [1])
C0677671 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
C1522449 (UMLS CUI [5])
C0543467 (UMLS CUI [6])
C0003280 (UMLS CUI [7])
C0003211 (UMLS CUI [8])
C0600558 (UMLS CUI [9])
C0021081 (UMLS CUI [10])
C2348568 (UMLS CUI [11])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial